Western Australia has never had trouble digging things out of the ground, but turning laboratory research into a globally competitive company has always been the harder trick. That is what makes the latest recognition for Perth cardiologist and researcher Professor Girish Dwivedi worth pausing on. He has been named the recipient of the state Pearcey entrepreneur award, an honour that celebrates people who take Australian technology out of the lab and into the market, and his win puts a spotlight on a health-tech sector that has been quietly building momentum on the west coast.
The award was reported this week by TechDay Australia, which noted that his work in artificial intelligence for cardiac diagnostics now spans hospitals, universities and start-ups. That span is the whole point. In a country that produces world-class medical research but frequently watches the commercial upside disappear overseas, an individual who can operate credibly across all three worlds is rare, and increasingly valuable.
Who is being recognised, and why
Girish Dwivedi is a practising cardiologist and a senior medical researcher based in Perth, where his work has focused on using machine learning to interpret cardiac imaging. The clinical problem he has spent years attacking is a familiar one to anyone who has sat in a cardiology waiting room. Heart disease remains one of the leading causes of death in Australia, and much of the diagnostic process still relies on specialist eyes reading complex scans, a process that is slow, expensive and uneven in its accuracy depending on who is doing the reading.
The promise of AI cardiac diagnostics is to bring speed and consistency to that task, flagging the patients most at risk of a heart attack earlier and with more confidence. Dwivedi’s contribution has been to help move that promise from a research paper toward tools that clinicians can actually use, and to do so while keeping one foot in the hospital, one in the university and one in the commercial sector. The Pearcey judges have effectively rewarded that ability to translate, which is precisely the capability Australia says it wants more of.
The Pearcey pedigree
The Pearcey awards are named after Trevor Pearcey, the British-Australian scientist who led the team that built CSIRAC, one of the world’s first digital computers, in the late 1940s. The awards exist to honour people who carry that pioneering spirit forward, and the state-level entrepreneur categories are designed to surface founders and innovators who might not otherwise get national attention. Winning the Western Australian award places Dwivedi in a lineage of technologists the sector holds up as role models, and it hands the broader Perth ecosystem a useful story to tell about itself.
Two ways of reading the win
There is an optimistic reading and a more cautious one, and both are worth airing. The optimistic case is that Dwivedi’s recognition signals a genuine maturing of WA health-tech. For years the state’s innovation narrative was dominated by resources technology and mining automation. A cardiac AI researcher taking the top entrepreneur gong suggests the base is broadening, and that medical research institutes and universities in Perth are starting to produce commercial talent rather than just publications. Supporters of that view would point to the way his work knits together clinical practice and start-up activity as exactly the kind of dense, cross-sector collaboration that healthy innovation clusters are built on.
The more cautious reading is that individual awards, however deserved, do not by themselves fix the structural gaps that have long held Australian medtech back. Regulatory approval for AI-driven diagnostic tools is slow and demanding, and rightly so given the stakes. Reimbursement pathways through the health system are notoriously difficult to navigate, which means a clinically brilliant tool can still struggle to find a sustainable business model. Access to the kind of patient capital that lets a medical device company survive the years between prototype and revenue remains thinner here than in the United States. On that view, celebrating a single entrepreneur is necessary but not sufficient, and the real test is whether the systems around him can carry a dozen more to the same point.
What it means for Australia
For the rest of the country, the win lands in the middle of a live debate about whether Australia is building AI capability or merely hosting other people’s. Much of the national conversation has fixated on data centres, sovereign compute and large language models, areas where Australia is often a customer rather than a creator. Applied health AI offers a different and arguably more defensible path. It plays to genuine local strengths, including a strong public research base, high-quality clinical datasets and a universal health system that, for all its funding pressures, gives innovators a real-world environment to test in.
If Australia wants sovereign AI capability that is more than a slogan, cardiac diagnostics is the kind of narrow, high-value niche where a mid-sized country can plausibly lead the world. The catch is that leadership in a niche still requires the boring machinery of commercialisation to work, including clear regulatory guidance from the Therapeutic Goods Administration, faster reimbursement decisions, and investors willing to back deep-science companies with long horizons. A Perth cardiologist proving it can be done is encouraging. It is not a substitute for the policy scaffolding that would let others follow.
What is next
The immediate question is whether the recognition translates into momentum. Awards tend to open doors, and for a founder juggling clinical duties with commercial ambitions, greater visibility can mean easier access to capital, partners and talent. Watch for whether WA can convert this moment into a coherent health-tech identity the way it has done with mining technology, and whether other states, particularly the larger medical research hubs in Melbourne and Sydney, respond by pushing their own applied AI health projects harder.
For patients, the longer arc is the one that matters most. If tools born from this kind of research reach the clinic at scale, the payoff is earlier detection of heart disease and fewer preventable deaths. That is a slow story that will play out over years rather than headlines. For now, the west coast has a fresh reminder that its innovation future need not be measured only in tonnes shipped, and that some of its most valuable exports may end up being lines of code trained to read a human heart.
Sources: TechDay Australia.
